The study provides insights into the metabolic adaptation of EMT-induced carboplatin resistant cells that confers on them reduced proliferation to provide effective migratory advantage; and the role of some of these identified proteins in ovarian cancer prognosis. These observations warrant further ...
Platinum is a key component of ovarian cancer systemic therapy. However, most patients will eventually face a recurrence, leading to chemotherapy resistance, especially against platinum. For individuals with platinum-resistant ovarian cancer (PROC), treatment options are limited, and their survival prospe...
also mediates retrograde signaling. Cisplatin-resistant ovarian cancer cells exhibit high levels of PGC-1α, boosting mitochondrial biogenesis and reducing apoptosis [44]. In SKOV3/DDP cells, mitochondria ROS production stimulates the nucleus, increasing PGC1α expression and contributing to drug resistan...
Platinum is a key component of ovarian cancer systemic therapy. However, most patients will eventually face a recurrence, leading to chemotherapy resistance, especially against platinum. For individuals with platinum-resistant ovarian cancer (PROC), treatment options are limited, and their survival prospe...
induced carboplatin resistant cells that confers on them reduced proliferation to provide effective migratory advantage; and the role of some of these identified proteins in ovarian cancer prognosis. These observations warrant further investigation of these novel target proteins in platinum-resistant patients...
Patients recurring with 6 months within the end of platinum-based chemotherapy are characterized by poor prognosis. To date no effective treatment modality are identified for those patients. The mainstay of treatment for platinum-resistant ovarian cancer is single agent chemotherapy. Other treatment ...
To further confirm that C/EBPβ promotes cisplatin resistance in ovarian cancer, C/EBPβ was overexpressed in OV2008, which is a cisplatin-sensitive cell line with negligible C/EBPβ expression, and C/EBPβ was knocked down in C13* cells, which are cisplatin-resistant derivatives of OV2008 ...
www.nature.com/scientificreports OPEN AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin Susann Badmann1, Doris Mayr2, Elisa Schmoeckel2, Anna Hester1, Christina Buschmann1, Susanne Beyer1, Thomas Kolben1, Fabian Kraus1, Anca ...
Lee created a nomogram to predict the prognosis in ovarian cancer. This prognostic nomogram was developed and generated by the pretreatment characteristics such as patients' performance, tumor size, or CA-125, etc., under multivariable proportional hazards models. Further, Dr. Lee applied their ...
Women with ovarian cancer who experience disease progression during or within 6 months of first-line treatment with platinum-based anticancer drugs are considered to have platinum-resistant tumors. These patients have an unfavorable prognosis, and they frequently seek complementary and alternative therapies...